Predictive data to preserve health
Delivering and exploiting data for cardiac decompensation prevention
Trusted by clinical, academic and innovation partners
CHU Caen Normandie
inserm
Lyonbiopole
Medicalps
The Outcomes We Pursue
Keep Patient at Home
Delay Loss of Autonomy
Reduce Avoidable Hospitalizations
The Scale of Heart Failure
People living with heart failure worldwide
Is 2x Population of Texas
Annual heart failure hospitalizations in the USA and EU
The #1 cause of hospitalization in patients over 65
Is 3x COPD hospitalizations
Annual direct heart failure costs in the USA and EU
Is comparable to the economic burden of stroke across the two regions
Where Current Care Falls Short
More patients every year — the population living with heart failure is growing 3% annually.
Of readmitted patients had no cardiology follow-up after discharge
Of annual heart-failure costs come from hospitalizations alone.
From Reactive Care to Preventive Care
Just as continuous glucose monitoring transformed diabetes, pressure-guided therapy will transform heart failure.
Hospital-centered
- Reactive care
- High costs
- Limited capacity
Continuous
hemodynamic monitoring
Early detection.
Therapy adaptation.
Pathology stabilization.
Home-centered
- Preventive and continuous care
- Lower costs
- Scalable access
Our ambition: to make hemodynamic monitoring at home the new standard in heart failure care.
How the CardiaMetrics Solution Works
Subcutaneous sensor
Intracardiac pressures
estimation model
Pressure-guided
therapy
Predict deterioration up to 30 days before hospitalization
Discover more about
Our Technology | View Clinical Evidence
The Impact of Earlier Intervention
Organizational impact
Preserving quality of life
Supporting better outcomes for patients while helping healthcare teams manage more people with fewer avoidable hospitalizations.
Our Next Clinical Milestone
We are about to launch our first human trial in partnership with the Caen hospital (Normandy, France).